Search Results - "Key, Nigel S."

Epidemiologic and clinical data linking factors XI and XII to thrombosis by Key, Nigel S

“…Currently available evidence supports the contention that elevated levels of factor XI (fXI) are associated with a greater risk of venous thromboembolism and…”
Get full text

The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues by Campello, Elena, Ilich, Anton, Simioni, Paolo, Key, Nigel S.

“…It has long been recognised that pancreatic cancer induces a hypercoagulable state that may lead to clinically apparent thrombosis. Although the relationship…”
Get full text

Neutrophils: back in the thrombosis spotlight by Noubouossie, Denis F., Reeves, Brandi N., Strahl, Brian D., Key, Nigel S.

“…Reactive and clonal neutrophil expansion has been associated with thrombosis, suggesting that neutrophils play a role in this process. However, although there…”
Get full text

Microparticle analysis in disorders of hemostasis and thrombosis by Mooberry, Micah J., Key, Nigel S.

“…Microparticles (MPs) are submicron vesicles released from the plasma membrane of eukaryotic cells in response to activation or apoptosis. MPs are known to be…”
Get full text

D-dimer antigen: current concepts and future prospects by Adam, Soheir S., Key, Nigel S., Greenberg, Charles S.

“…The D-dimer antigen is a unique marker of fibrin degradation that is formed by the sequential action of 3 enzymes: thrombin, factor XIIIa, and plasmin. First,…”
Get full text

Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis by Mackman, Nigel, Tilley, Rachel E, Key, Nigel S

“…Hemostasis requires both platelets and the coagulation system. At sites of vessel injury, bleeding is minimized by the formation of a hemostatic plug…”
Get full text

Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis by Gordeuk, Victor R, Key, Nigel S, Prchal, Josef T

“…Here we critically evaluate the role of elevated hematocrit as the principal determinant of thrombotic risk in polycythemia and erythrocytosis, defined by an…”
Get full text

Adverse clinical outcomes associated with sickle cell trait at high altitude by Stafford, Katherine A, Osataphan, Soravis, Patell, Rushad, Key, Nigel S

“…Not available.Not available…”
Get full text

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A by Mahlangu, Johnny, Kaczmarek, Radoslaw, von Drygalski, Annette, Shapiro, Susan, Chou, Sheng-Chieh, Ozelo, Margareth C., Kenet, Gili, Peyvandi, Flora, Wang, Michael, Madan, Bella, Key, Nigel S., Laffan, Michael, Dunn, Amy L., Mason, Jane, Quon, Doris V., Symington, Emily, Leavitt, Andrew D., Oldenburg, Johannes, Chambost, Hervé, Reding, Mark T., Jayaram, Kala, Yu, Hua, Mahajan, Reena, Chavele, Konstantia-Maria, Reddy, Divya B., Henshaw, Joshua, Robinson, Tara M., Wong, Wing Yen, Pipe, Steven W.

“…Participants with hemophilia A received B-domain–deleted factor VIII gene therapy delivered in an AAV5 vector. A decrease in annualized bleeding rates was…”
Get full text

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update by LYMAN, Gary H, KHORANA, Abk A, KAKKAR, Ajay K, KEY, Nigel S, LEVINE, Mark N, LIEBMAN, Howard A, TEMPERO, Margaret A, WONG, Sandra L, ALEXIS PRESTRUD, Ann, FALANGA, Anna, KUDERER, Nicok M, LEE, Agnes Y, IGNACIO ARCELUS, Juan, BALABAN, Edward P, CLARKE, Jeffrey M, FLOWERS, Christopher R, FRANCIS, Charles W, GATES, Leigh E

“…To provide recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. Prophylaxis in the outpatient, inpatient,…”
Get full text

Blood Coagulation: Hemostasis and Thrombin Regulation by Tanaka, Kenichi A., Key, Nigel S., Levy, Jerrold H.

“…Perioperative bleeding is a major challenge particularly because of increasing clinical use of potent antithrombotic drugs. Understanding current concepts of…”
Get full text

Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways by Noubouossie, Denis F., Henderson, Michael W., Mooberry, Micah, Ilich, Anton, Ellsworth, Patrick, Piegore, Mark, Skinner, Sarah C., Pawlinski, Rafal, Welsby, Ian, Renné, Thomas, Hoffman, Maureane, Monroe, Dougald M., Key, Nigel S.

“…Storage lesion–induced, red cell–derived microvesicles (RBC-MVs) propagate coagulation by supporting the assembly of the prothrombinase complex. It has also…”
Get full text

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives by Young, Guy, Sørensen, Benny, Dargaud, Yesim, Negrier, Claude, Brummel-Ziedins, Kathleen, Key, Nigel S.

“…Hemophilia is a bleeding disorder that afflicts about 1 in 5000 males. Treatment relies upon replacement of the deficient factor, and response to treatment…”
Get full text

Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors by Hisada, Yohei, Grover, Steven P, Maqsood, Anaum, Houston, Reaves, Ay, Cihan, Noubouossie, Denis F, Cooley, Brian C, Wallén, Håkan, Key, Nigel S, Thålin, Charlotte, Farkas, Ádám Z, Farkas, Veronika J, Tenekedjiev, Kiril, Kolev, Krasimir, Mackman, Nigel

“…Pancreatic cancer is associated with a high incidence of venous thromboembolism. Neutrophils have been shown to contribute to thrombosis in part by releasing…”
Get full text

Using heparin molecules to manage COVID‐2019 by Liu, Jian, Li, Jine, Arnold, Katelyn, Pawlinski, Rafal, Key, Nigel S.

“…The coronavirus disease 2019 (COVID‐19) pandemic is becoming one of the largest global public health crises in modern history. The race for an effective drug…”
Get full text

Coagulation factor concentrates: past, present, and future by Key, Nigel S, Dr, Negrier, Claude, MD

“…Summary Clotting factor transfusions are vital for people with diseases such as haemophilia. In the 1970s and 1980s, transfusions with pooled plasma led to a…”
Get full text

Analysis of tissue factor positive microparticles by Key, Nigel S

“…Abstract There has recently been intense interest in the clinical measurement of tissue factor (TF)-positive microparticles (MPs) in clinical disease states…”
Get full text

Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease by Sparkenbaugh, Erica M., Chantrathammachart, Pichika, Mickelson, Jacqueline, van Ryn, Joanne, Hebbel, Robert P., Monroe, Dougald M., Mackman, Nigel, Key, Nigel S., Pawlinski, Rafal

“…Activation of coagulation and vascular inflammation are prominent features of sickle cell disease (SCD). Previously, we have shown that inhibition of tissue…”
Get full text

Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure by Stravitz, R. Todd, Bowling, Regina, Bradford, Robert L., Key, Nigel S., Glover, Sam, Thacker, Leroy R., Gabriel, Don A.

“…Microparticles (MPs), membrane fragments of 0.1‐1.0 μm, are derived from many cell types in response to systemic inflammation. Acute liver failure (ALF) is a…”
Get full text

Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer by Wang, Jian-Guo, Geddings, Julia E., Aleman, Maria M., Cardenas, Jessica C., Chantrathammachart, Pichika, Williams, Julie C., Kirchhofer, Daniel, Bogdanov, Vladimir Y., Bach, Ronald R., Rak, Janusz, Church, Frank C., Wolberg, Alisa S., Pawlinski, Rafal, Key, Nigel S., Yeh, Jen Jen, Mackman, Nigel

“…Cancer patients often have an activated clotting system and are at increased risk for venous thrombosis. In the present study, we analyzed tissue factor (TF)…”
Get full text